Aileron Therapeutics, a biotech targeting a range of cancers using stapled peptides, raised $56 million by offering 3.8 million shares at $15, the low end of the range of $15 to $17.
Aileron Therapeutics plans to list on the Nasdaq under the symbol ALRN. BofA Merrill Lynch and Jefferies acted as lead managers on the deal.
